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Although the efﬁcacy of pharmacotherapy for tobacco dependence has been previously demonstrated, there
is substantial variability among individuals in treatment response. We performed a systems-based candidate
gene study of 1295 single nucleotide polymorphisms (SNPs) in 58 genes within the neuronal nicotinic recep-
tor and dopamine systems to investigate their role in smoking cessation in a bupropion placebo-controlled
randomized clinical trial. Putative functional variants were supplemented with tagSNPs within each gene. We
used global tests of main effects and treatment interactions, adjusting the P-values for multiple correlated
tests. An SNP (rs2072661) in the 30 UTR region of the b2 nicotinic acetylcholine receptor subunit
(CHRNB2) has an impact on abstinence rates at the end of treatment (adjusted P 5 0.01) and after a 6-
month follow-up period (adjusted P 5 0.0002). This latter P-value is also signiﬁcant with adjustment for the
number of genes tested. Independent of treatment at 6-month follow-up, individuals carrying the minor
allele have substantially decreased the odds of quitting (OR 5 0.31; 95% CI 0.18–0.55). Effect of estimates
indicate that the treatment is more effective for individuals with the wild-type (OR 5 2.14, 95% CI 1.20–
3.81) compared with individuals carrying the minor allele (OR 5 0.83, 95% CI 0.32–2.19), although this differ-
ence is only suggestive (P 5 0.10). Furthermore, this SNP demonstrated a role in the time to relapse (P 5
0.0002) and an impact on withdrawal symptoms at target quit date (TQD) (P 5 0.0009). Overall, while our
results indicate strong evidence for CHRNB2 in ability to quit smoking, these results require replication in
an independent sample.
INTRODUCTION
Use of tobacco is the single greatest preventable cause of
death in the USA, with a substantial impact on morbidity
and mortality worldwide. One in ﬁve Americans is a current
smoker, and available therapies are efﬁcacious for only a
small fraction of those who attempt to quit (1). Bupropion,
an anti-depressant therapy, is among the only two
FDA-approved non-nicotine pharmacotherapies available for
the treatment of nicotine dependence. While its efﬁcacy is
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ity in therapeutic response (2–4), and most smokers do not
maintain long-term abstinence (5,6). Pharmacogenetic
studies may improve the outcomes of bupropion therapy for
smoking cessation by identifying smokers most and least
likely to beneﬁt based on inherited differences in drug metab-
olism and CNS targets. Such studies may also identify genetic
markers of relapse risk, thereby identifying smokers who may
require more intensive treatment.
Genes coding for nicotinic acetylcholine receptor (nAChRs)
and genes within the dopamine reward system are plausible
candidates for pharmacogenetic investigations of bupropion.
Nicotine activates a4b2 nAChRs to stimulate dopamine
release, which plays a key role in signaling the reward
system (7). Bupropion inhibits dopamine re-uptake, resulting
in higher levels of dopamine, which is believed to be respon-
sible for alleviating the cognitive and affective symptoms of
nicotine withdrawal, as demonstrated in preclinical (8,9) and
human studies (8,10,11). Consistent with these data, several
studies have identiﬁed associations of single nucleotide poly-
morphisms (SNPs) in dopaminergic and nAChR subunit
genes with nicotine dependence (12–16) and with smoking
cessation during the treatment with bupropion (17–22).
While the a4b2 nAChRs account for the majority of high afﬁ-
nity binding related to dopamine release, nAChRs on dopa-
minergic neurons may also contain a5, a6 and b3 subunits,
which may contribute to receptor targeting, localization and
receptor permeability (23).
The present analysis was undertaken to extend prior phar-
macogenetics research on prospective smoking cessation
beyond individual polymorphisms or single gene analyses.
Using data from a placebo-controlled randomized clinical
trial of bupropion for smoking cessation (20), we explored
the associations of 1295 SNPs within 58 candidate gene
regions in the dopamine system, including nAChRs and intra-
cellular signaling proteins. A systems-based approach and
analysis has many advantages over the evaluation of single
functional polymorphisms and single candidate gene
approaches. By taking a more expansive approach to SNP
selection and gene selection, we hope to provide more com-
plete coverage of the underlying genetic variation within a
suspected etiologic system. This is accomplished in two
ways. In addition to the inclusion of putative functional poly-
morphisms, we have included a set of SNPs to comprehen-
sively capture the underlying genetic architecture within
each candidate gene. Likewise, by broadening our selection
of candidate genes to include multiple genes in a intercon-
nected system, rather than simply focusing on single puta-
tively interesting genes, we hope to provide a more
complete picture of the impact of the entire system. This
potentially allows for the identiﬁcation of sets of markers in
the presence of some system redundancy. Thus, we have lever-
aged biological knowledge in the selection of both SNPs and
genes while also including broad SNP coverage within each
gene and an expanded selection of genes across the entire
dopamine system. Our analysis mimics this structure in
which we ﬁrst perform tests of single SNPs for main effects
and SNP X treatment interactions, while adjusting the level
of signiﬁcance for all SNPs within each gene. Then, taking a
more global perspective, we further adjust for the number of
genes used to characterize the entire system. Then, based
upon ﬁndings from this analysis, we use our biological knowl-
edge to guide us in testing the haplotypic effects and inter-
actions with other relevant candidate genes.
RESULTS
Descriptive data
The genetic association analyses were performed on persons
with self-identiﬁed European ancestry only (Table 1). This
included 222 individuals receiving bupropion and 195 individ-
uals receiving placebo. There were slightly more females
(54%) than males, and the average age was 44 (SD ¼ 11)
years. Similar distributions of the Fagerstro ¨m Test for Nic-
otine Dependence (FTND) were observed between the treat-
ment and placebo groups with a mean FTND of 5.1 (SD ¼
2.1) and 5.2 (SD ¼ 2.2), respectively. At the end of treatment
(EOT), there was a 32.0% abstinence rate in the bupropion
group when compared with 21.5% in the placebo group.
This corresponds to a treatment OR ¼ 1.76 (95% CI 1.12–
2.76). Abstinence rates were decreased at 6-month follow-up
with 25.7% of those individuals receiving bupropion remain-
Table 1. Study characteristics
Buproprion,
n (%)
Placebo,
n (%)
217 195
Age 44.0+11.8 44.6+11.2
Gender Female 120 (55.3%) 106 (54.4%)
Male 97 (44.7%) 89 (45.6%)
FTND
a 0 2 (0.9%) 2 (1%)
1 9 (4.1%) 13 (6.7%)
2 10 (4.6%) 10 (5.1%)
3 22 (10.1%) 15 (7.7%)
4 42 (19.4%) 31 (15.9%)
5 42 (19.4%) 30 (15.4%)
6 33 (15.2%) 32 (16.4%)
7 26 (12%) 34 (17.4%)
8 19 (8.8%) 21 (10.8%)
9 10 (4.6%) 6 (3.1%)
10 2 (0.9%) 1 (0.5%)
Mean 5.1+2.1 5.2+2.2
End of treatment
b Abstinent 70 (32.3%) 42 (21.5%)
Relapsed 147 (67.7%) 153 (78.5%)
6-month follow-up
b Abstinent 56 (25.8%) 34 (17.4%)
Relapsed 161 (74.2%) 161 (82.6%)
Average withdrawal
symptoms at TQD
c
32.3+7.2 30.7+7.3
Average days to
smoking relapse
d
45.2+50.5 28.2+38.9
All the subjects were of European ancestry.
aScores for the Fagerstro ¨m test for nicotine dependence (FTND) were assessed
at baseline.
bSmoking abstinence or relapse was biochemically assessed and veriﬁed at the
end of treatment (8 weeks following target quit date [TQD]) and 6-months after
the target quit date.
cWithdrawal symptoms at the TQD were assessed on 18 items (e.g. irritability,
insomnia, nausea), each scored from 0 (no symptoms) to 3 (severe symptoms).
Scores in this study ranged from 18 to 60.
dDays to smoking relapse up to the 6-month follow-up period was self-reported
by subjects. The average days to relapse exclude subjects who self-reported
abstinence throughout the entire study period.
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nent (treatment OR ¼ 1.66; 95% CI 1.03–2.69). These treat-
ment effects are consistent with prior research (24). For
individuals who relapsed during the 6-month follow-up
period, the average for time to ﬁrst cigarette was 45.2 days
(SD ¼ 50.5) in the bupropion group and 28.2 days (SD ¼
38.9) in the placebo group (P ¼ 0.0016). At target quit data
(TQD), the bupropion group had higher mean withdrawal
symptoms (32.3, SD ¼ 7.2) compared with the placebo
group (30.7, SD ¼ 7.3) (P ¼ 0.04). Of our original 1295 can-
didate gene SNPs, 97 (7.5%) were excluded from further
analysis after genotyping because they were monomorphic
or had low (, 0.01) minor allele frequencies in our samples.
The remaining 1198 SNPs had an r
2 of 0.8 or greater with
85% of all the common (.0.05%) SNPs within the 58 candi-
date genes in the current version of HapMap (Genome Build
36, Table 2) (see Supplementary Material, Table S3 for infor-
mation regarding all the SNPs).
Associations with abstinence at end of treatment and
6-month follow-up
Results from the single SNP analyses are presented in Table 3
for EOT and 6-month follow-up, respectively. Only SNPs with
an adjusted P-value ,0.05 from a likelihood ratio test (LRT)
and with stable effect estimates are presented in the tables.
Results for all the SNPs are presented in Supplementary
Material, Tables S1 and S2. Two SNPs within the 30 UTR
of the CHRNB2 (cholinergic receptor, nicotinic, beta 2)
gene show a substantial impact on relapse at the EOT with
an observed LRT P-value for the most signiﬁcant SNP
(rs2072661) of 9.97   10
24 and an adjusted P-value of
1.33   10
22. The two SNPs in CHRNB2 are in strong
linkage disequilibrium (r
2 ¼ 0.96) with each other and their
effect estimates following a similar trend with both SNPs
demonstrating a dominant genetic model. For simplicity in
presentation, we focus on reporting the result for rs2072661.
Irrespective of treatment, having the minor allele for
rs2072661, which was present in 23% of our subjects,
decreases the odds of quitting substantially (OR ¼ 0.40;
95% CI 0.25–0.67, P ¼ 0.0004). The interaction effect with
treatment is not signiﬁcant at an a ¼ 0.05 level (P ¼ 0.97);
treatment OR for wild-type (WT) genotype ¼ 1.77 (95% CI
1.02–3.07) and for minor allele OR ¼ 1.81 (95% CI 0.79–
4.14). At 6-months follow-up, the genetic effect for
rs2072661 becomes more pronounced (OR ¼ 0.31; 95% CI
0.18–0.55; P ¼ 0.00006) and there is a more noticeable differ-
ence in the treatment effects by genotype, with treatment being
substantially more effective for quitting the WT genotype
group (OR ¼ 2.14; 95% CI 1.20–3.81) when compared with
the treatment effect within the individuals carrying the
minor allele (OR ¼ 0.83; 95% CI 0.32–2.19). A test for
SNP-treatment interaction yields a P-value ¼ 0.10. In addition
to the two original SNPs within CHRNB2 showing an effect at
EOT, there are three additional SNPs in LD with rs2072661
(rs1127314, rs2131902, and rs3766927) 30 of the CHRNB2
gene with substantial genetic effects and signiﬁcantly adjusted
P-values from the LRT at 6-month follow-up.
SNP rs10517626 within the TDO2 (tryptophan
2,3,-dioxygenase) gene was also found to be noteworthy and
has similar patterns of effects at EOT and at 6-month
follow-up. Speciﬁcally, at EOT there is a genetic effect
enhancing quit rates for each additional minor allele (OR ¼
1.81; 95% CI 1.10–2.99; P ¼ 0.01) with the treatment
effect being more effective within those individuals carrying
the minor allele (OR ¼ 3.98; 95% CI 1.60–9.91) when
compared with the treatment effect within individuals with
the WT genotype (OR ¼ 1.39; 95% CI 0.84–2.31). The differ-
ence in treatment effects by genotype is suggestive of an
observed P-value from the interaction test of 4.26   10
22.
Additional polymorphisms at EOT are indicated in
ADCYAP1 and HTR1B or at 6-month follow-up in CDK5
and FOSB, but none are consistent with the analyses at both
time points.
To examine the LD patterns within the CHRNB2 gene, we
investigated the block structure using Haploview (25) and
the CEPH (Centre d’Etude du Polymorphisme Humain) from
Utah (CEU) HapMap (version 23a) samples. Figure 1 presents
the LD patterns for 24 SNPs spanning the CHRNB2 gene with
HapMap genotype data. Of these, 22 SNPs have MAF .0.05
and two SNPs were forced in the selection process because of
prior information (rs2072658 and rs2072661). Our 13 tagSNPs
captured 20 of the 22 total common HapMap SNPs with SNPs
rs9427092 and rs3766925 not tagged at an r
2 of 0.8 or greater.
The LD structure indicates two distinct block regions with sig-
niﬁcant and suggestive SNPs from the single SNP analyses
located within the second block. Using the eight genotyped
SNPs within this region, we estimated six common haplotypes
explaining 98% of the total frequency in the sample (Table 4).
A haplotype analysis using the haplotype carrying the most
common alleles for all the SNPs as the referent indicates
that there is a signiﬁcant global LRT at EOT (P ¼ 0.03) and
at 6-month follow-up (P ¼ 0.007). In the analysis at both
time points, the haplotypes carrying the minor allele for
rs2072661 and rs2072660 (haplotypes 11001011 and
11101011) have odd ratios indicating increased relapse rates.
Any haplotype without these minor alleles shows no effect
further indicating that either rs2072661 or rs2072660 are
driving the effect in this region. We further conﬁrmed the
independent effect of either r2072661 or rs2072660 by per-
forming a joint regression model on a subset of SNPs in this
region (results not shown). However, because of the high
amount of correlation between these two SNPs, we were
unable to differentiate the independent effect of each SNP.
To demonstrate more clearly the impact of SNP rs2072661
on the abstinence rates, we examined in more detail the pat-
terns of relapse from EOT to 6-month follow-up. Figure 2 pre-
sents the abstinence rates for all the individuals and stratiﬁed
by rs2072661. As reﬂected in the odds ratio estimates for the
genetic effect, the abstinence rates are lower for those individ-
uals who carry the minor allele (AA or AG). This impact is
greater at 6-month follow-up. Interestingly, from EOT to
6-month follow-up, individuals carrying the minor allele
who had received bupropion during the treatment phase had
the greatest reduction in abstinence once treatment ended.
While not statistically signiﬁcant (P ¼ 0.10), for all the indi-
viduals carrying the minor allele who were treated with bupro-
pion, the abstinence rate was 22.4% at EOT and decreased to
10.6% at 6-month follow-up. To further quantify this impact,
we performed an analysis examining the abstinence rates at
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Gene symbol Gene name Chromosome Total HapMap
SNPs
b
tagSNPs Coverage
e
Selected
c Analyzed
d
DRD1IP (Calcyon) dopamine receptor D1 interacting protein 10 18 6 6 0.82
ADCYAP1 adenylate cyclase activating polypeptide 1 18 74 24 23 0.83
ANKK1_DRD2
a 11 194 55 52 0.97
ANKK1 ankyrin repeat and kinase domain containing 1
DRD2 dopamine receptor D2
BDNF brain-derived neurotrophic factor 11 87 28 26 0.96
CALM1 calmodulin 1 (phosphorylase kinase, delta) 14 53 11 10 0.82
CDK5 cyclin-dependent kinase 5 7 26 11 10 0.87
CHRNA2 cholinergic receptor, nicotinic, alpha 2 8 97 27 26 0.88
CHRNA5_CHRNA3_CHRNB4
a 15 108 30 30 0.93
CHRNA5 cholinergic receptor, nicotinic, alpha 5
CHRNA3 cholinergic receptor, nicotinic, alpha 3
CHRNB4 cholinergic receptor, nicotinic, beta 4
CHRNB3_CHRNA6
a 8 79 8 7 0.50
CHRNA6 cholinergic receptor, nicotinic, alpha 6
CHRNB3 cholinergic receptor, nicotinic, beta 3
CHRNA4 cholinergic receptor, nicotinic, alpha 4 20 61 12 12 0.62
CHRNA7 cholinergic receptor, nicotinic, alpha 7 15 168 33 33 0.91
CHRNB2 cholinergic receptor, nicotinic, beta 2 1 48 13 13 0.92
CLIC6 chloride intracellular channel 6 21 73 21 18 0.98
CNR1 cannabinoid receptor 1 (brain) 6 91 21 21 0.74
COMT catechol-O-methyltransferase 22 84 35 28 0.88
CREB1 cAMP responsive element binding protein 1 2 63 18 17 0.94
CREBBP CREB binding protein (Rubinstein-Taybi
syndrome)
16 229 30 27 0.80
CRHR1 corticotropin releasing hormone receptor 1 17 76 18 16 0.86
DBH dopamine beta-hydroxylase (dopamine
beta-monooxygenase)
9 129 42 36 0.85
DDC dopa decarboxylase (aromatic L-amino acid
decarboxylase)
7 334 50 47 0.87
DRD1 dopamine receptor D1 5 89 34 32 0.80
DRD3 dopamine receptor D3 3 107 26 24 0.95
DRD4 dopamine receptor D4 11 33 12 11 0.63
DRD5 dopamine receptor D5 4 41 12 8 0.91
EPB41 erythrocyte membrane protein band 4.1
(elliptocytosis 1, RH-linked)
1 202 48 44 0.99
EPB41L1 erythrocyte membrane protein band 4.1-like 1 20 230 25 16 0.97
EPB41L2 erythrocyte membrane protein band 4.1-like 2 6 445 51 49 0.81
FLNA ﬁlamin A, alpha (actin binding protein 280) X 35 11 5 1.00
FOSB FBJ murine osteosarcoma viral oncogene
homolog B
19 27 7 7 0.58
GNAS GNAS complex locus 20 127 32 31 0.85
GNAZ guanine nucleotide binding protein (G protein),
alpha z polypeptide
22 114 24 22 0.94
GRB2 growth factor receptor-bound protein 2 17 110 23 23 0.97
HCRTR1 hypocretin (orexin) receptor 1 1 37 11 11 1.00
HCRTR2 hypocretin (orexin) receptor 2 6 224 56 54 0.98
HTR1A 5-hydroxytryptamine (serotonin) receptor 1A 5 26 6 6 0.88
HTR1B 5-hydroxytryptamine (serotonin) receptor 1B 6 66 29 27 0.93
KCNJ9 potassium inwardly-rectifying channel,
subfamily J, member 9
1 32 11 10 0.95
KLF16 Kruppel-like factor 16 19 24 6 6 0.68
MAOA_MAOB
a X 223 42 40 0.95
MAOA monoamine oxidase A
MAOB monoamine oxidase B
MAPK1 mitogen-activated protein kinase 1 22 141 28 27 0.97
NCK1 NCK adaptor protein 1 3 86 25 25 0.94
FREQ (NCS1) frequenin homolog (Drosophila) 9 114 42 40 0.80
NR4A2 nuclearreceptorsubfamily 4, groupA, member2 2 33 10 9 0.83
NTRK1 neurotrophic tyrosine kinase, receptor, type 1 1 120 14 10 0.22
OPRM1 opioid receptor, mu 1 6 421 46 44 0.47
POMC proopiomelanocortin 2 35 16 12 0.85
PPP1R1B protein phosphatase 1, regulatory (inhibitor)
subunit 1B (DARPP-32)
17 26 9 9 1.00
PRKAR2B protein kinase, cAMP-dependent, regulatory,
type II, beta
7 153 36 32 0.95
Continued
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nent at EOT (n ¼ 112). For rs2072661, the P-value from the
2 degree-of-freedom LRT was 0.047. Of note, for those indi-
viduals who received bupropion, the impact of rs2072661
was substantial for decreasing the odds of quitting, once the
individuals were no longer on treatment (OR ¼ 0.25; 95%
CI 0.08–0.78).
Time to relapse
The pattern described above is also reﬂected when examining
time to ﬁrst relapse (Figure 3).
We note that relapse rates used in the time to relapse
analysis are not directly comparable to the relapse rates
presented in Figure 2, as the time-dependent information on
relapse is via self-report and daily use can not be biochemi-
cally veriﬁed. Throughout the course of the trial and follow-up
period, individuals with the WT genotype and received
bupropion had the highest abstinence rates. Those individuals
carrying the minor allele and who received buporpion
had higher abstinence rates during the trial as compared to
placebo, but those rates dropped to those of placebo by 6-
month follow-up. A 2-df LRT for the gene and gene-treatment
interaction from a Cox regression yielded a P-value of 0.0002.
Withdrawal symptoms
We examined the impact of rs2072661 on withdrawal symp-
toms measured using the withdrawal symptom severity index
at TQD, coinciding with the peak symptoms, for those individ-
uals who were abstinent (CO levels ,10 ppm) for the week
post-TQD. Because bupropion has been shown to impact with-
drawal symptoms (26), we stratiﬁed our analysis by treatment
from a linear regression on all the individuals receiving
placebo, there was a 3.8 unit greater magnitude of withdrawal
severity for individuals carrying the minor allele compared
with those having the WT genotype (P ¼ 0.0009). In contrast,
for those who received bupropion, there was only a 0.45 unit
difference between the two groups (P ¼ 0.71).
Interaction with CHRNA4
Finally, as the a4b2 nAChR is the most widely distributed
subtype nAChR, we investigated the interaction effect of
the 11 SNPs genotyped within the CHRNA4 gene and
rs2072661 at EOT and at 6-month follow-up. None of the
interaction tests were signiﬁcant at an a-level of 0.05. For
example, within individuals with the WT genotype for
rs2236196, a known functionally signiﬁcant SNP in
CHRNA4 (14), the CHRNB2 SNP rs2072661 effect reduced
quit rates (OR ¼ 0.39; 95% CI 0.24–0.65). In contrast, for
those individuals with a minor allele for rs2236196, the
impact on quit rates was negligible (OR ¼ 0.89; 95% CI
0.31–2.50). While qualitatively suggestive, the P-value for
the interaction test was only 0.11. At 6-month follow-up, the
effect of rs2072661 did not differ by CHRNA4 rs2236196
carrier status.
DISCUSSION
Using a systems-based candidate gene approach we have
identiﬁed polymorphisms within the b2 nicotinic acetyl-
choline receptor (CHRNB2) that exhibits signiﬁcant associ-
ation with the abstinence rates at EOT and at 6-month
follow-up in a placebo-controlled trial of bupropion for
smoking cessation. The association with abstinence was
observed for two highly correlated (r
20.96) SNPs
(rs2072661 and rs2072660) within the 30UTR. Although the
effects were independent of treatment, there was an indication
of potential effect modiﬁcation by bupropion. Speciﬁcally,
although there was a difference in relapse rates at EOT
between carriers and non-carriers for individuals who received
bupropion, there was a substantial increase in relapse rates for
those individuals carrying the minor allele after they went off
treatment (Figure 2). Haplotype analysis capturing the genetic
variability within the region conﬁrmed the association across
multiple SNPs and further indicated the independent role of
the two SNPs. However, because of the high correlation
between these SNPs, joint regression modeling was unable
to discern the independent effect of each. Follow-up analyses
on the top SNP (rs2072661) indicated a role in the time to
Table 2. Continued
Gene symbol Gene name Chromosome Total HapMap
SNPs
b
tagSNPs Coverage
e
Selected
c Analyzed
d
PICK1 (PRKCABP) protein interacting with PRKCA 1 22 51 16 14 1.00
SLC6A3 solute carrier family 6, member 3 (dopamine
transporter)
5 145 27 26 0.78
SNCA synuclein, alpha (non A4 component of amyloid
precursor)
4 243 39 39 0.99
TDO2 tryptophan 2,3-dioxygenase 4 56 12 12 0.82
TH tyrosine hydroxylase 11 50 16 15 0.67
5958 1295 1198 0.88
aWhen selecting SNPs, overlapping genes were treated as a single gene region.
bThe total number of HapMap SNPs was obtained from Genome Build 36.
ctagSNPs were selected using pairwise r
2 within gene regions.
dThose that had a call rate of zero or minor allele frequency lower than 0.01 were excluded from the analysis.
eCoverage is calculated as the proportion of HapMap SNP with r
2 greater than 0.80 with the tagSNPs analyzed.
2838 Human Molecular Genetics, 2008, Vol. 17, No. 18Table 3. Single nucleotide polymorphism (SNP)-speciﬁc results for abstinence rates
SNP Gene Chromosome Position Minor allele
frequency
a
Genetic
model
b
SNP OR (95% CI) Treatment OR Test of
interaction
c
Likelihood ratio test
d
Wild type (95% CI) Variant (95% CI) Observed P Adjusted P
End of treatment
rs2072661 CHRNB2 1 152,815,504 0.23 Dom 0.40 (0.25–0.67) 1.77 (1.02–3.07) 1.81 (0.79–4.14) 9.70   10
21 9.97   10
24 1.33   10
22
rs2072660 CHRNB2 1 152,815,345 0.23 Add 0.50 (0.32–0.76) 1.51 (0.88–2.59) 2.33 (1.11–4.88) 3.28   10
21 2.86   10
23 2.34   10
22
rs12961210 ADCYAP1 18 890,523 0.32 Add 1.85 (1.33–2.57) 2.15 (1.07–4.31) 1.86 (1.14–3.03) 6.74   10
21 1.15   10
23 2.59   10
22
rs2565059 CHRNA2 8 27,392,895 0.19 Add 2.32 (1.46–3.68) 1.76 (0.98–3.16) 2.06 (1.11–3.83) 7.97   10
21 1.49   10
23 3.14   10
22
rs1936158 HTR1B 6 78,241,094 0.41 Dom 0.53 (0.33–0.84) 3.14 (1.52–6.49) 1.14 (0.63–2.07) 3.51   10
22 1.20   10
23 3.43   10
22
rs10517626 TDO2 4 157,050,894 0.10 Add 1.81 (1.10–2.99) 1.39 (0.84–2.31) 3.98 (1.6–9.91) 4.26   10
22 4.03   10
23 4.16   10
22
6-month follow-up
rs2072661 CHRNB2 1 152,815,504 0.23 Dom 0.31 (0.18–0.55) 2.14 (1.20–3.81) 0.83 (0.32–2.19) 1.01   10
21 1.54   10
25 2.40   10
24e
rs2072660 CHRNB2 1 152,815,345 0.23 Dom 0.33 (0.19–0.58) 2.04 (1.15–3.63) 0.86 (0.33–2.26) 1.32   10
21 4.33   10
25 6.36   10
24e
rs2069454 CDK5 7 150,383,915 0.14 Dom 2.07 (1.18–3.62) 1.12 (0.61–2.05) 5.03 (1.93–13.1) 9.38   10
23 3.71   10
24 4.73   10
23
rs1127314 CHRNB2 1 152,822,890 0.30 Add 0.52 (0.35–0.78) 1.71 (0.92–3.15) 1.53 (0.79–2.96) 7.95   10
21 3.67   10
23 2.77   10
22
rs2238687 FOSB 19 50,665,006 0.13 Add 2.22 (1.4–3.52) 1.74 (0.97–3.15) 1.59 (0.74–3.43) 8.48   10
21 3.68   10
23 3.05   10
22
rs10517626 TDO2 4 157,050,894 0.10 Add 1.96 (1.17–3.28) 1.31 (0.76–2.28) 3.46 (1.37–8.76) 6.98   10
22 3.23   10
23 3.34   10
22
rs2131902 CHRNB2 1 152,826,222 0.31 Dom 0.47 (0.29–0.76) 1.78 (0.94–3.37) 1.43 (0.67–3.04) 6.62   10
21 6.42   10
23 4.47   10
22
rs3766927 CHRNB2 1 152,830,765 0.30 Dom 0.47 (0.29–0.78) 1.83 (0.97–3.46) 1.35 (0.63–2.90) 5.47   10
21 6.79   10
23 4.53   10
22
rs13152449 TDO2 4 157,055,252 0.10 Add 1.94 (1.15–3.25) 1.34 (0.77–2.31) 3.45 (1.35–8.82) 7.74   10
22 4.61   10
23 4.55   10
22
aEstimate minor allele frequency in our study sample.
bFor each SNP, dominant (Dom) and additive (Add) genetic models were estimated and the model yielding the lower adjusted P-value was selected.
cThe test of interaction is the observed P-value from a test of heterogeneity for the treatment odds ratios.
dThe likelihood ratio test observed P-value was obtained using a joint 2-df test combining the genetic marginal effect and the gene–treatment interaction effect. Adjusted P-values were estimated by
accounting for the correlation between observed SNPs within the respective gene regions. This adjustment was also used when selecting a genetic model.
eAfter adjustment, rs2072661 and rs2072660 reached pathway level signiﬁcance (P , 0.0009) at 6-month follow-up. All models were adjusted for age, gender, and FTND.
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9relapse within the 6-month follow-up period and an impact on
withdrawal symptoms at TQD. Investigation of a functionally
signiﬁcant SNP within CHRNA4, a biologically relevant inter-
action since the a4b2 nAChRs form a common subtype,
demonstrated a suggestive, albeit non-signiﬁcant, interaction.
Evidence for the important role of CHRNB2 in smoking
cessation is consistent with the animal studies demonstrating
the involvement of b2 subunit-containing nAChRs in nicotine-
mediated release of dopamine and in the nicotine withdrawal
syndrome. Nicotine reduces, and withdrawal increases the
brain stimulation reward-thresholds in rodents (27,28),
effects which are mediated largely via a4b2 nAChRs (29).
Further, compared with WT mice, knockout mice lacking
the b2 subunit exhibit attenuated nicotine self-administration
and reduced nicotine stimulated dopamine release in the
ventral striatum (30), as well as reductions in conditioned nic-
otine reinforcement (31,32). Effects of nicotine, and nicotine
withdrawal, on cognitive function are also attenuated in b2
knockout mice (33,34).
Human imaging studies indicate that nicotine from a single
cigarette nearly completely saturates a4b2 nAChRs (35), and
abstinence from nicotine is associated with an increase in the
number of unbound b2-containing nAChRs, and thus increas-
ing urge to smoke (36). Based on these observations, genes
encoding nAChR subunits have been a focus of a number of
previous genetic studies of nicotine dependence. A recent
study reported associations of initial subjective responses to
nicotine with an SNP immediately upstream of CHRNB2
and one of the two 30 UTR SNPs (rs2072660) identiﬁed by
the present study (37). Other candidate gene studies that
Figure 1. Block structure for CHRNB2 from HapMap Genome Build 36. The linkage disequilibrium (LD) plot was obtained using Haploview (25) and HapMap
Build 36. The scale at the top of the ﬁgure depicts the HapMap region for CHRNB2 (Chromosome 1: 152,806,881 to 152,818,975), and roughly 10 kb upstream
and downstream of this region. Single nucleotide polymorphisms (SNPs) genotyped by HapMap are identiﬁed in blue (minor alleles) and red (major alleles).
Gene regions with the direction of their respective reading frame, exons, and introns, are also given. The 13 SNPs in boxes are the tagSNPs selected in this gene
region. rs2072658 and rs2072661 have no HapMap or LD information. The r
2 LD color scheme is depicted. Two blocks are delineated using the default block
deﬁnitions from Haploview.
2840 Human Molecular Genetics, 2008, Vol. 17, No. 18have examined one or both of the two CHRNB2 30 UTR SNPs,
along with additional SNPs in CHRNB2, have not found
association with nicotine dependence at CHRNB2 (15,38–
40) in a variety of community- and population-based
samples of smokers. In addition, an analysis using smokers
and non-smokers that included the two CHRNB2 30 UTR
SNPs and rs2236196 at CHRNA4 to detect gene–gene
interactions associated with nicotine dependence failed to
detect signiﬁcant interaction (41). However, nicotine depen-
dence only modestly predicts smoking cessation in response
to bupropion (4) and twin studies of the genetic relationship
between the two phenotypes suggest that the two phenotypes
may have differing genetic contributions [reviewed by
Lessov-Schlaggar et al. (42)]. Of note, neither the genes in
the dopamine pathway examined here, including those impli-
cated in prior studies, nor the CHRNA3/CHRNA5 gene
cluster associated with nicotine dependence in recent reports
(15,43–46) reached the threshold of signiﬁcance for associ-
ation with smoking cessation or treatment response.
The present study has both strengths and limitations.
Strengths include the prospective evaluation of abstinence in
the setting of a placebo-controlled trial and collection of
DNA samples from all participants, rather than retrospective
DNA collection that may result in bias. With regards to the
molecular genetic analysis, strengths include conservative
SNP selection, robust genotyping, and extensive quality
control. Because we performed our SNP selection on an
early version of HapMap, we opted to use a high r
2 cutoff
(0.95) in selecting tagSNPs and including all singleton
SNPs. This proved to be a prudent strategy as our set of
SNPs captured on an average 85% of the existing common
SNPs in the current version of HapMap. While this strategy
resulted in a higher number of correlated SNPs within each
gene, this did not have a detrimental impact on the analysis
as we accounted for the correlation in our multiple testing pro-
cedures. Furthermore, a slight level of redundancy in SNP
coverage allowed for a more stringent criteria for the
removal of SNPs with low call rates, resulting in 97% of the
analyzed SNPs having call rates .95%. SNPs with low call
rates were driven mostly by genotyping failures for individuals
with whole genome-ampliﬁed DNA for that particular SNP
only. Thus, when there was a discrepancy between call rates
for individuals with genomic DNA and individuals with
WGA DNA, we limited our analysis to only those individuals
with genomic DNA. Finally, for the top SNP rs2072661, there
was a 97% concordance between the genotypes obtained from
the Illumina assay versus genotypes obtained using TaqMan
w
(Applied Biosystems, Foster City, CA, USA) assay (data not
shown). When we compared carriers versus non-carriers, i.e.
a dominant model, we observed 100% concordance.
Another strength of the current study was the genotyping of
233 ancestry informative SNPs to assess intercontinental
admixture within individuals of the same self-identiﬁed ethni-
city (47–49). These SNPs were genotyped on individuals from
multiple ethnic groups and analyses investigating the structure
used the frequency of SNPs within each self-identiﬁed group
to more accurately deﬁned ancestry proportions for any
given individual. These ancestry estimates were not only
used to visually inspect the levels of admixture within
Caucasians, but also to empirically compare unadjusted esti-
mates to those adjusted by ancestry proportions. Although
we demonstrated that the structure did not impact the analyses,
we limited our ﬁnal analyses to only Caucasians, as LD pat-
terns can vary substantially across ethnic groups and may
lead to heterogeneity in effect estimates, thus negatively
impacting power despite the inclusion of additional samples.
Finally, our rankings and determination of interesting SNPs
was based on an adjusted P-value obtained using a method that
accounts for multiple correlated tests when ﬁrst determining
the genetic model and then across all SNPs within each candi-
date gene region. This resulting adjusted P-value is less con-
servative than a uniform adjustment across the number of
SNPs that assumes independence (i.e. Bonferroni correction),
but more stringent than simply ignoring the evaluation of mul-
tiple SNPs. This analysis does not yield evidence for an inde-
pendent effect for each SNP. Here, we used both haplotype
and joint regression modeling. However, we do view this
adjusted P-value to be the evidence for both a particular
SNP and for the gene since the SNPs were originally chosen
to capture the common variation within the gene. These
adjusted P-values may then be compared with the appropriate
signiﬁcance level for the type of hypothesis of interest. Since
the genes were chosen to capture the important components
within the entire system, we use a conservative signiﬁcance
a-level of 0.0009 across the 54 gene regions to indicate
signiﬁcance at the system-level. We did not adjust the
P-values in our presentation because we believe a transparent
presentation of the results is necessary to emphasize associ-
ations that are consistent with previous knowledge and to
highlight the need for replication of unexpected results. For
example, several additional genes (TDO2, ADCYAP1,
HTR1B, CDK5, and FOSB) have at least one SNP achieving
an adjusted P-value of ,0.05, but they are not signiﬁcant at
the systems level. These genes are still of interest as there
are varying amount of prior evidence for each (50–53). In
addition, there are several recent reports of genes (e.g.
DRD1, DRD2, DRD3, ANKK1, BDNF, and NTRK2) within
the dopamine system being involved in nicotine dependence
(13,54–56). While there are some SNPs within these genes
Table 4. Haplotype analysis of the 30-UTR region in CHRNB2
Haplotype
a Frequency End of treatment, OR
(95% CI)
6-month follow-up, OR
(95% CI)
00000000 0.23 1.00 1.00
00010100 0.27 1.17 (0.76–1.80) 1.06 (0.68–1.66)
00000100 0.19 1.00 (0.62–1.60) 0.86 (0.52–1.42)
11001011 0.14 0.64 (0.38–1.07) 0.50 (0.28–0.89)
11101011 0.07 0.43 (0.20–0.92) 0.29 (0.12–0.73)
00001011 0.07 1.31 (0.67–2.53) 0.94 (0.46–1.93)
  – –  b 0.98 LRT P-value ¼ 0.03
c LRT P-value ¼ 0.007
c
aThe second block shown in Figure 1. Common alleles in each haplotype
are designated by ‘0’, and variant alleles designated by ‘1’. The haplotype
carrying the common alleles for all the SNPs was used as the referent
allele.
bFrom Table 3, those SNPs with adjusted P-values ,0.05 are indicated by
asterisks. The ﬁrst two SNPs are rs2072660 and rs2072661, respectively.
cThe likelihood ratio test (LRT) P-value is from a global test of the full
haplotype model versus a covariate-only model. Covariates include age,
gender, FTND, and treatment.
Human Molecular Genetics, 2008, Vol. 17, No. 18 2841that have observed P-values ,0.05 (e.g. DRD1 and DRD2)i n
the current study, none of these genes have SNPs with signiﬁ-
cantly adjusted P-values. Furthermore, none of the reported
SNPs are signiﬁcant in the current study (see Supplementary
Material, Tables S1 and S2 for complete results). While this
may be owing to the difference in phenotypes, conﬁrmation
of results by further studies is the key to valid conclusions
in this area of research (57). In addition, systems-based
analyses may be performed, which more formally integrates
prior knowledge via ontologies into the identiﬁcation and
testing of relevant associations (58–61).
For our top SNP we were able to perform speciﬁc additional
analyses motivated by prior knowledge to reﬁne its potential
mechanism of impact via time to relapse, withdrawal symp-
toms, and interaction effects with a key biologically relevant
gene, CHRNA4. Having a detailed phenotypic information
prospectively gathered from a randomized placebo-controlled
trial was crucial for this further analysis. However, the collec-
tion of detailed information limited the original size of the
study and thus we were unable to conclusively determine via
statistical criteria SNP-treatment or SNP–SNP interactions,
although effect estimates were suggestive in some instances.
Although we included individuals from several ethnic groups
for the investigation of population structure, we were unable
to conﬁrm our ﬁndings across all the self-identiﬁed ethnic
groups because of the limited sample size for groups other
than Caucasians.
While independent replication will ultimately be required,
the results of the present study may have important impli-
cations for the treatment of nicotine dependence. We found
strong and consistent evidence for the association of two
CHRNB2 30 UTR SNPs with multiple phenotypes assessed
in the current trial, including abstinence at both EOT and
6-month follow-up, days to relapse, and nicotine withdrawal
symptoms. While the literature provides four independent
examples of the lack of association of these two CHRNB2
SNPs with nicotine dependence, these SNPs may be robust
markers for identifying smokers most likely to relapse and
those who may beneﬁt from bupropion therapy. In addition,
these SNPs should be examined within pharmacogenetic
studies of varenicline, a new a4b2 nAChR partial agonist
medication for smoking cessation. Future studies should also
extend molecular genetic analysis to include the large 30
UTR of CHRNB2 (39) and a novel set of nAChR-interacting
proteins that regulate b2 nAChR signaling (62). For
example, the 30 UTR of CHRNB2, extends some 4 kb 30 of
the coding region, and contains seven predicted human micro-
RNA targets, including a target for human miR-432 located
13 base pairs 50 of rs2072660 (63).
MATERIALS AND METHODS
Study sample and design
The individuals in the study were enrolled in a bupropion
double-blind placebo-controlled pharmacogenetic smoking
cessation trial conducted by the University of Pennsylvania
Transdisciplinary Tobacco Use Research Center. All appropri-
ate IRB approvals were obtained by participating institutions
as part of the Pharmacogenetics of Nicotine Addiction and
Treatment Consortium. Smokers were recruited from April
1999 to October 2001 at Georgetown University (Washington,
DC, USA) and SUNY Buffalo (New York, USA). Details of
the eligibility criteria and ﬂow of participants through the
enrollment, treatment, and follow-up phases of the trial can
be found elsewhere (20). Brieﬂy, trial participants included
600 smokers who were .18 years of age, and reported
smoking more than 10 cigarettes a day for the prior 12
months. Exclusion criteria included pregnancy, a history of
DSMIV axis I psychiatric disorder, seizure disorder, and
current use of antidepressants or other psychotropic medi-
cations. All participants in the trial provided informed
Figure 2. Abstinence rates by CHRNB2 rs2072661 and by bupropion treatment. Abstinence rates comparing individuals with at least one variant allele for
CHRNB2 rs2072661 (ﬁlled bars) to those with both common alleles (unﬁlled bars) were stratiﬁed by treatment (buproprion or placebo) and estimated at
each time point (end of treatment and 6-month follow-up).
2842 Human Molecular Genetics, 2008, Vol. 17, No. 18consent for both genotyping and treatment; however, at the
time of this genotyping analysis, samples remained for 534
subjects. Analyses were limited to individuals of European
ancestry with both phenotype and genotype data (n ¼ 412).
Although we examine population structure within all 534
individuals of differing self-identiﬁed ethnicities, we limit
our primary analyses to only those individuals who self-
identiﬁed as Caucasian because of the potential for differential
linkage disequilibrium across ethnic groups to lead to
heterogeneity of effect estimates.
Participants from both the sites received identical assess-
ments and treatments. At an initial visit to the smoking
clinic, participants provided a 40 mL blood sample and com-
pleted a set of standardized self-report questionnaires. Base-
line nicotine dependence was assessed via the FTND (64).
All participants received 10 weeks of either placebo or bupro-
pion. Bupropion treatment was delivered according to the
standard therapeutic dose (150 mg/day for the ﬁrst 3 days, fol-
lowed by 300 mg/day). All participants also received seven
sessions of standardized behavioral group counseling, focus-
ing on self-monitoring and behavioral modiﬁcation
approaches. All participants were instructed to quit smoking
on a TQD 2 weeks after initiating medication and counseling.
Smoking status was assessed by telephone interview at the
EOT (8 weeks post-TQD) and at 6 months after the TQD
using a validated timeline followback method (65). Inter-
viewers were blind to study group assignment. Participants
who reported complete abstinence (not even a puff of a ciga-
rette) for at least the 7 days prior to the assessment were asked
to complete an in-person visit for biochemical veriﬁcation of
abstinence. Saliva cotinine testing was performed for partici-
pants who reported abstinence at a given time-point using a
gas–liquid chromatography method (66). Cotinine is the
major proximate metabolite of nicotine and has a much
longer half-life than nicotine, making it the preferred
biomarker for tobacco use.
Phenotype assessment
The primary outcome was 7-day point prevalence abstinence
(biochemically conﬁrmed) at the EOT and 6-month follow-up.
Participants were classiﬁed as abstinent if (1) they self-
reported abstinence and (2) they had a cotinine reading of
 15 ng/ml. Of the total 412 self-identiﬁed Caucasian individ-
uals successfully genotyped, 187 participants self-reported
abstinence at EOT (45%) and 133 of these individuals
(71%) provided a sample for cotinine veriﬁcation. At
6-months, 118 participants reporting abstinence (29%) and
89 (75%) of these individuals provided a sample. Those who
failed to complete the follow-up or failed to provide a biosam-
ple for biochemical veriﬁcation were presumed to have
relapsed, as per convention (67). Of the 412 individuals, 112
were biochemically veriﬁed as abstinent at EOT and 90
during 6-month follow-up.
Secondary outcomes included days to relapse following the
TQD (using Cox proportional hazards modeling) and withdra-
Figure 3. Time to relapse to 6-month follow-up for CHRNB2 rs2072661. Time to relapse to 6-month follow-up in individuals with at least one variant allele for
CHRNB2 rs2072661 (thin lines) was compared with those having both alleles common (thick lines), stratifying by treatment group: buproprion (dotted lines) and
placebo (solid lines).
Human Molecular Genetics, 2008, Vol. 17, No. 18 2843wal symptoms. For the time to relapse analysis, self-reported
abstinence for the past 7 days at weekly intervals up to
6-month follow-up was used. We assessed withdrawal symp-
toms on the TQD using a self-report checklist assessing the
severity (in the past 7 days) of common symptoms, including
irritability, difﬁculty in concentrating, anxiousness, insomnia,
drowsiness, nausea and general physical complaints (e.g.
sweating, dizziness). Responses to each item was scored
from 0¼ not at all to 3 ¼ severe and were summed to create
a withdrawal severity index (total scores could range from
18 to 60).
Gene and single nucleotide polymorphism selection
We selected 58 candidate genes using a comprehensive bioin-
formatic approach incorporating expert opinion, automated lit-
erature searches, and public pathway databases. The candidate
gene list includes several neuronal nicotinic acetylcholine
receptors (nAchRs) and genes in the dopamine-mediated
reward system, including dopamine receptors, dopamine trans-
porter, and enzymes involved in biosynthesis and metabolism.
Additional addiction-related secondary messenger pathway
genes, and genes hypothesized to play a role in modulating
the dopamine pathway owing to upstream signaling (e.g. ser-
otonin pathway) and those with direct physical interaction
with dopamine receptors were also included. The complete
list of genes is presented in Table 1.
Of our total of 1528 SNPs genotyped, 233 were ancestry
informative markers (AIMs) and 1295 were used to capture
the underlying genetic structure within our candidate genes.
The AIMs were speciﬁcally selected to differentiate four par-
ental populations (African, European, American Indian, and
East Asian) (68) within each individual and for making
precise estimates of coefﬁcient of ancestry (69,70) and princi-
pal components (71) for each individual. We have previously
genotyped these AIMs in a multi-ethnic sample from the Mul-
tiethnic Cohort Diversity Panel (72) and demonstrated the
ability of these polymorphisms to identify levels of ancestral
populations within a single individual.
For SNP selection within each candidate gene, we used a
beta version of the Snagger software (73). We used HapMap
SNP data from the CEPH and Chinese populations [Genome
Build 35 (74)]. Because several of our selected candidate
genes are located adjacent to each other on a chromosome,
we performed our tagSNP selection across 54 regions of inter-
est, expanding each region 10 kb upstream and downstream.
Of the 1295 SNPs selected, 118 were of interest because of
their putative function and, conditional on including these,
an additional 1185 SNPs were selected to capture the under-
lying genetic structure. For each SNP in a gene, an LD bin
was created containing all SNPs in the gene region meeting
an r
2 threshold of 0.95 with that speciﬁc SNP. From these
bins, we preferentially selected tag SNPs using several cri-
teria: Illumina design scores (quantifying how well a SNP
can be genotyped), validation status (indicating how many
platforms validate a SNP), minor allele frequency (MAF),
and location (i.e. coding region). To ensure efﬁcient Illumina
genotyping, a potential tagSNP would not be selected if it was
within 60 bp of another chosen SNP or 35 bp of any other
known SNP in dbSNP. Because of the potential for some
SNPs to fail in the genotyping, redundant tagSNPs were
selected if the number of SNPs in a bin was large. Those
SNPs that could not be tagged (i.e. singletons) were also
included if their design score was greater than 0.4. Tag
SNPs were ﬁrst chosen in the CEPH population. If necessary
to capture the diversity within the Chinese HapMap population
sample, additional SNPs were selected. Genetic diversity
within Chinese individuals was captured as part of a
companion study within the USC Transdisciplinary Tobacco
Use Research Center (75).
Genotyping
We performed all genotyping of the SNPs using the Gold-
enGateTM assay, which uses the Illumina platform (Illumina,
San Diego, CA, USA) at the Genomics Core Facility at
USC/Norris Comprehensive Cancer Center. We had various
levels of quality control. This included automated protocols
for the entire genotyping process utilizing robotics and
barcoding, and the inclusion of replicates and CEPH trios to
aid in genotyping and identiﬁcation of errors. After initial
auto-clustering, each SNP is edited to deﬁne three genotypes
with the intent of maximizing call rate and minimizing
possible error rate. Genotype calls are then evaluated for
ﬁve criteria: (1) HapMap is queried for the results of the
CEPH trios for each SNP and compared with our genotype
calls; (2) replicate and trio errors are calculated for all
plates/samples in a project; (3) non-informative frequency is
calculated for each SNP; (4) deviation from the expected
heterozygosity is determined; and (5) MAF is calculated.
These criteria are used to identify any SNPs with genotyping
errors that may require additional visual inspection, re-calling,
or determination that a ‘no call’ be made.
Among the 1528 total SNPs, we excluded 41 SNPs with a
call rate of zero and 57 SNPs with an observed MAF
,0.01. There were a total of 1430 SNPs available for analysis
(1198 SNPs within the candidate genes and 232 AIMs). Of the
remaining SNPs, 97% had a SNP call rate  95%. Of the 1198
SNPs within the candidate genes, a total of eight SNPs had a
P-value of ,0.0001 from an exact test of Hardy–Weinberg
proportions. The genotyping calls for these SNPs were
re-examined, conﬁrmed, and included in the analysis (76–79).
After exclusion of 41 SNPs, individual call rates were cal-
culated using the entire multi-ethnic sample (n ¼ 548) and
after stratifying by DNA type, i.e. genomic (gDNA) and
whole genome ampliﬁed (wgaDNA) DNA. Individuals with
a call rate ,90% were removed from the analysis (n ¼ 14)
for a total of 500 individuals with gDNA and 34 individuals
with wgaDNA. While there was a substantial difference
between the call rate distributions for the gDNA samples
(99.6% of individuals with a call rate  95%) in comparison
with the wgaDNA samples (85.3% of individuals with a call
rate  95%), inspection of Illumina data for SNPs with drasti-
cally discordant SNP call rates between the two DNA types
revealed reliable genotyping calls for SNPs with a SNP call
rate calculated using only wgaDNA samples of  80%.
Thus, for 51 SNPs in which the SNP call rate was  80%
for wgaDNA samples, we only report analyses using the indi-
viduals with gDNA samples.
2844 Human Molecular Genetics, 2008, Vol. 17, No. 18Statistical analysis
Single nucleotide polymorphism-speciﬁc association. We used
a generalized linear model to evaluate the individual SNPs:
gðmYÞ¼a þ b   XG þ g   XTx þ d   XTx   XG þ u   W
Here, g(mY) is a link function deﬁning the speciﬁc general-
ized linear model. We used a logistic link for relapse outcomes
at both EOT and 6-month follow-up. Thus, the corresponding
effect estimates (e.g. b, g, and d) represent the log OR and the
estimated parameter values are used to calculate the OR for
the treatment of the WT genotype and the ORs for an
additional risk allele. A Cox proportional hazards model was
used for the time to relapse analysis. XG deﬁned the genetic
model as either additive or dominant and was mean-centered
after determination of the genetic model. For all SNPs, the
more common genotype was chosen as the referent. Because
of the potential for small data bias, we did not examine the
recessive model. For a given SNP, individuals with missing
genotypes were excluded from the analysis. XTx was mean-
centered and indicated if an individual received Bupropion
for treatment. W deﬁned the covariates used in the analysis
with all covariates mean-centered. For our basic analysis, cov-
ariates included gender, age, and FTND. All analyses were
performed among smokers who initiated therapy; consistent
with an intent-to-treat analysis, those who withdrew were
included in the analysis and were assumed to have returned
to smoking.
We used a joint 2-df LRT to combine information from the
genetic marginal effect (b) and the gene–treatment interaction
effect (d) as the primary test. Speciﬁcally, this test constrained
both b ; 0 and d ; 0 under the null hypothesis and was
shown previously to provide good power across a wide
range of underlying true causal models (80). Using this
model, we ﬁrst determined the most appropriate genetic
model by testing both dominant and additive genetic models.
The best ﬁtting genetic model as determined by the model
yielding the lowest P-value, was then used in all the sub-
sequent analyses. Regression analyses were performed using
the R Statistical Program (81).
Correcting for correlated tests within a gene and determining
system-level signiﬁcance. To account for the correlated tests
from the determination of a genetic model for a given SNP
and for the multiple correlated tests from the SNPs within
each gene region, we performed a P-value adjustment for cor-
related tests. Speciﬁcally, the tests statistics are modeled as an
asymptotically distributed multivariate normal with a
co-variance structure estimated from the correlation of
observed SNPs (82). This adjustment was performed ﬁrst on
the test statistics obtained by modeling dominant and additive
genetic models for each SNP. The resulting adjusted P-values
were then further adjusted to account both for the correlation
and the number of tests performed across the SNPs within a
gene region. The ﬁnal adjusted P-value is reported and was
used to rank the SNPs. System-level signiﬁcance is determined
using a Bonferroni correction across the 54 gene regions.
Thus, for a family-wise or system-wide a-level we use 0.05/
54 ¼ 0.0009.
Investigation of confounding by population stratiﬁcation. The
entire study sample of 534 smokers was pooled with an
additional 577 individuals from the University of Pennsylva-
nia Nicotine Replacement Trial (20) and 355 individuals
from the Multi-Ethnic Cohort Diversity Panel (72) that
included African-Americans, Asians, Native Hawaiians,
Latinos, and Caucasians. These individuals provide reference
ethnic groups and help to better estimate the admixture
within a given individual. The program STRUCTURE was
used to estimate the coefﬁcient of ancestry for each individual
(69) and principal component analysis was used to estimate
the principal components for each individual (81). For the
STRUCTURE analysis, the best ﬁtting analysis estimated
four ancestral populations within the combined sample:
African, Caucasian, Asian, and Amerindian. The ancestral
populations and estimated amounts of admixture within each
individual corresponded well with the ﬁrst four principal com-
ponents—components that explained 39% of the variation
with all the other components explaining 1% or less of the
variation each. Visual inspection showed very little individual
admixture within each self-identiﬁed ethnic group, indicating
a small potential for confounding because of population stra-
tiﬁcation. In addition, we empirically tested the impact of
population structure on the analysis by running the base
model adjusted for coefﬁcients of ancestry or principal com-
ponents within the self-identiﬁed ethnic groups. The effect
estimates obtained from the adjusted analysis were neither
substantially different in comparison with the unadjusted
analysis nor did the corresponding P-values change consider-
ably. Thus, we did not adjust for the variability captured by
the coefﬁcients of ancestry or principal components within
the self-reported ethnicity when analyzing the Caucasian-
only sample. However, we limited the analyses to only the
individuals who self-identiﬁed as Caucasian because of
the potential for differential linkage disequilibrium across
different ethnic groups leading to heterogeneity in effect
estimates.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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